Exploiting the advantages of Concurrent PET/SPECT: In vivo SPECT/PET/CT imaging with 99mTc-HSA (vascularity) and 64Cu-ATSM (hypoxia)
In vivo examination of vascularity and hypoxia in tumors is important in understanding cancer biology and for the development of therapeutic strategies. It’s becoming apparent that cancer treatment may need advanced strategies by e.g. combining antiangiogenic, antivascular, and antihypoxia therapies. For the first time, it’s now possible to image and quantitate the combined effect of such therapies with single in vivo imaging sessions.
The authors of this publication demonstrate this innovation in cancer imaging by using the MILabs’ VECTor PET/SPECT/CT system to clearly distinguish 99mTc-HSA uptake regions (blood pool) and 64Cu-ATSM uptake regions (hypoxia) in a HT29 xenograft, with both tracers being imaged at exactly the same time.
In Vivo Simultaneous Imaging of Vascular Pool and Hypoxia with a HT-29 Tumor Model:
The Application of Dual-Isotope SPECT/PET/CT
Adachi et al., International Journal of Sciences:
Basic and Applied Research, 2016
VECTor image demonstrates excellent true simultaneous quantitative in vivo acquisition of SPECT (99mTc) and PET (64Cu) tracers.
This publication utilizes the MILabs VECTorTM imaging system to:
Perform concurrent in vivo PET and SPECT imaging.
Quantitate simultaneously acquired 64Cu and 99mTc images.
Exploit virtually unlimited combinations of PET and SPECT tracers.
Explore single and dual tracer imaging over a wide linear response range.
MILabs products are used in more than 65 countries and are supported by a global network of distributors and factory trained support engineers.
Please contact MILabs directly for more information about your local MILabs business partner.